What is typical empiric MRSA and Pseudomonas coverage for hospital-acquired pneumonia?

• A. Piperacillin-tazobactam alone
• B. Cefepime alone
• C. Vancomycin plus piperacillin-tazobactam
• D. Vancomycin or linezolid plus an anti-pseudomonal beta-lactam (e.g., piperacillin-tazobactam or cefepime); may add aztreonam if penicillin allergy

Answer: (D)

The main idea is that hospital-acquired pneumonia commonly involves MRSA and Pseudomonas, so initial therapy should cover both pathogens until cultures guide narrowing. The best approach combines an MRSA-active agent (vancomycin or linezolid) with an anti-pseudomonal beta-lactam (such as piperacillin-tazobactam or cefepime). This dual coverage addresses the two most feared groups while you wait for microbiology results. If the patient has a penicillin allergy, aztreonam can be added for anti-pseudomonal coverage, while MRSA coverage with vancomycin or linezolid is continued. The key point is pairing MRSA coverage with anti-pseudomonal beta-lactam therapy, with a sensible allergy-based substitution when needed.